S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
US banks adopt radical new technology (growing 24,290%) (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
US banks adopt radical new technology (growing 24,290%) (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
US banks adopt radical new technology (growing 24,290%) (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
US banks adopt radical new technology (growing 24,290%) (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
NASDAQ:ADXS

Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis

$0.97
+0.18 (+22.78%)
(As of 02/21/2024 ET)
Today's Range
$0.79
$0.98
50-Day Range
$0.52
$1.31
52-Week Range
$0.51
$1.95
Volume
75,631 shs
Average Volume
36,449 shs
Market Capitalization
$10.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ADXS stock logo

About Ayala Pharmaceuticals Stock (NASDAQ:ADXS)

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

ADXS Stock Price History

ADXS Stock News Headlines

Porter Stansberry exposes $100 billion hoax
: Artificial Illusion They say it’s the “biggest advancement in modern history…” But THEY’RE WRONG. Artificial intelligence is an Artificial Illusion. Which means if you own AI stocks, you need to watch this film now before it’s too late.
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Ayala Pharmaceuticals Inc Ordinary Shares ADXS
Ayala Pharmaceuticals Inc (ADXS)
Armando Ayala
Ayala Pharmaceuticals, Inc. (ADXS)
Hubei Biocause Pharmaceutical
See More Headlines
Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/09/2021
Today
2/21/2024
Next Earnings (Estimated)
2/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADXS
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
-210,876.91%

Debt

Sales & Book Value

Annual Sales
$3.24 million
Book Value
($0.61) per share

Miscellaneous

Free Float
10,684,000
Market Cap
$10.43 million
Optionable
Not Optionable
Beta
1.51
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Ruth Ben Yakar Ph.D. (Age 54)
    Chief Exec. Officer
  • Dr. Stela Gangrenovitch Ph.D.
    Co-Founder, Chief Scientist Officer and Director
  • Mr. Mark Gengrinovitch LLB
    Co-Founder, Chief Financial Officer and Director














ADXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Ayala Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADXS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXS, but not buy additional shares or sell existing shares.
View ADXS analyst ratings
or view top-rated stocks.

How have ADXS shares performed in 2024?

Ayala Pharmaceuticals' stock was trading at $0.6670 at the beginning of the year. Since then, ADXS stock has increased by 45.4% and is now trading at $0.97.
View the best growth stocks for 2024 here
.

When is Ayala Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our ADXS earnings forecast
.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) announced its quarterly earnings data on Thursday, September, 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.02. The company earned $0.25 million during the quarter.

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), Vistagen Therapeutics (VTGN), Novavax (NVAX), Highpower International (HPJ), OPKO Health (OPK) and Athersys (ATHX).

How do I buy shares of Ayala Pharmaceuticals?

Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADXS) was last updated on 2/22/2024 by MarketBeat.com Staff